Professional Reference articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.
The CHA2DS2-VASc score (Birmingham 2009) was developed after identifying additional stroke risk factors in patients with atrial fibrillation (AF).
Go to the MDCalc CHA2DS2-VASc Score for Atrial Fibrillation Stroke Risk.
- Validation study included 1,084 patients with non-valvular AF, not on anticoagulation, over age 18 with ECG or Holter diagnosed AF in the ambulatory and hospital settings from 182 hospitals in 35 countries from 2003 to 2004 and had known thromboembolic status at one year from the Euro Heart Survey database.
- End point used was stroke or other thromboembolic event.
- Used previously developed Birmingham 2009 schema, under the acronym CHA2DS2-VASc.
- Study showed that as CHA2DS2-VASc score increased, rate of thromboembolic event within one year in non-anticoagulated patients with non-valvular AF increased as well.
- Considered score of 0 to be low risk for thromboembolic events (none seen in cohort at one year), score of 1 intermediate risk (0.6% rate at one year), and greater than 1 high risk (3% rate at one year).
Did you find this information useful?
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. Patient Platform Limited has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.